GSK and Sanofi announced an "unprecedented" partnership last month - with the goal...
FSD Pharma gets FDA approval for Phase II Covid-19 trial
FSD Pharma has received approval from the US Food and Drug Administration (FDA) to design a Phase IIa clinical trial of FSD-201 for the treatment of Covid-19.
BerGenBio starts bemcentinib dosing in ACCORD Trial
Norway-based biopharmaceutical firm BerGenBio has started dosing participants in the Phase II ACCORD clinical trial of bemcentinib to treat hospitalised Covid-19 patients.
Trevena partners with Imperial College London to assess TRV027
Biopharmaceutical company Trevena has partnered with Imperial College London to assess TRV027 in a Phase Ib clinical study for the treatment of acute lung injury related to acute respiratory distress syndrome (ARDS) in Covid-19 patients.
Relief Therapeutics and NeuroRx start enrolment for Covid-19 trial
Relief Therapeutics and its partner NeuroRx have started patient enrolment and treatment in a Phase IIb/III clinical trial of RLF-100 to treat acute respiratory distress syndrome (ARDS) caused by Covid-19.
Lilly starts Phase I trial of antibody therapy for Covid-19
Eli Lilly has started dosing participants in the Phase I clinical trial of antibody therapy LY-CoV555, which is intended to treat Covid-19 infection.
Remdesivir shows clinical improvement in Phase III Covid-19 trial
Gilead Sciences has reported positive top-line data from the Phase III SIMPLE clinical trial of remdesivir in hospitalised patients with moderate Covid-19 pneumonia.
Minerva Neurosciences’ roluperidone fails in Phase III study
Minerva Neurosciences has reported that roluperidone failed to meet endpoints in a Phase III clinical trial for the treatment of negative symptoms in schizophrenia.
Sun Pharma to trial Nafamostat for Covid-19 treatment
Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to conduct a clinical trial of pancreatitis drug, Nafamostat Mesilate, to treat Covid-19 patients in the country.
AstraZeneca’s Tagrisso improves survival in lung cancer patients
AstraZeneca has reported positive results from the Phase III ADAURA clinical trial of Tagrisso (osimertinib) in patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
UK researchers study anti-inflammatory drug camostat for Covid-19
Researchers at Cancer Research UK and its partners have initiated a clinical trial to study camostat, used to treat inflammation of the pancreas, as a potential therapy against Covid-19.